Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expirations, FDA trial updates, and global segment revenue for Salix or Bausch + Lomb can be buried deep inside Bausch Health Companies’ disclosures. That makes a 10-K or 8-K more than a compliance form—it’s a puzzle investors must solve before patent cliffs hit cash flow. If you’ve ever scanned 300 pages searching for Xifaxan sales or litigation reserves, you know the challenge.
Stock Titan turns those dense documents into clear answers. Our AI-powered summaries flag the exact paragraphs that matter inside each Bausch Health Companies quarterly earnings report 10-Q filing and highlight Bausch Health Companies 8-K material events explained in plain language. You can monitor Bausch Health Companies insider trading Form 4 transactions, receive Bausch Health Companies Form 4 insider transactions real-time alerts, and compare compensation from the latest Bausch Health Companies proxy statement executive compensation—all without leaving this page.
Every filing type is updated the moment EDGAR posts: the Bausch Health Companies annual report 10-K simplified for pipeline risk, Bausch Health Companies earnings report filing analysis for margin trends, and understanding Bausch Health Companies SEC documents with AI for patent litigation footnotes. Need quick context? Our platform links drug-specific revenue tables, clinical milestone disclosures, and Bausch Health Companies executive stock transactions Form 4 directly to AI explanations. Access Bausch Health Companies SEC filings explained simply, download originals, or read concise takeaways designed for analysts who value both speed and depth.
Bausch Health is asking shareholders to ratify a shareholder rights plan at a Special Meeting to be held via webcast on October 7, 2025 (record shareholders as of August 18, 2025 may vote). The Board adopted the Rights Plan on April 14, 2025 and issued one Right for each Voting Share outstanding at the Record Time. The Rights are intended to ensure all shareholders are treated equally in any unsolicited take-over bid and to discourage creeping acquisitions.
The Rights convert into purchase rights after a defined Separation Time if a person becomes an Acquiring Person (generally at a 20% Beneficial Ownership threshold). The Exercise Price is set at three times the 20-day average Market Price, and a Flip‑In Event can lead to significant dilution for an acquiror. The TSX has given conditional acceptance, and the Rights Plan requires reconfirmation by shareholders every third annual meeting to remain effective.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
